Future work should include detailed mechanistic studies such as identifying key downstream effectors of MAPK12 in ESCA, its interaction with telomere maintenance pathways, and its role in mediating chemoresistance, ideally using patient‐derived organoids or genetically engineered mouse models to better mimic the tumor microenvironment. The gene discussed is MAPK12; the disease is neoplasm.